Idecabtagene Vicleucel in Early Relapsed/Refractory Myeloma: Is There an Efficacy Benefit?
Early administration ide-cel in relapsed/refractory multiple myeloma is crucial for achieving deeper responses and should not be delayed; however, logistics and product availability remain critical components.